Glycoprotein 330/megalin (LRP-2) has low prevalence as mRNA and protein in brain microvessels and choroid plexus

被引:56
作者
Chun, JT
Wang, L
Pasinetti, GM
Finch, CE
Zlokovic, BV [1 ]
机构
[1] Univ So Calif, Childrens Hosp Los Angeles, Dept Neurol Surg, Los Angeles, CA 90033 USA
[2] Univ So Calif, Childrens Hosp Los Angeles, Div Neurosurg, Los Angeles, CA 90033 USA
[3] Univ So Calif, Childrens Hosp Los Angeles, Ethel Percy Andrus Gerontol Ctr, Los Angeles, CA 90033 USA
[4] Univ So Calif, Childrens Hosp Los Angeles, Dept Sci Biol, Los Angeles, CA 90033 USA
[5] CUNY, Mt Sinai Med Ctr, Dept Psychiat, Neuroinflammatory Res Ctr, New York, NY 10029 USA
关键词
gp330; clusterin; LDL receptor; blood-brain barrier; amyloid; choroid plexus;
D O I
10.1006/exnr.1999.7052
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Prior studies indicated that glycoprotein 330/(gp330)/megalin mediates transcytosis of apolipoprotein J (apoJ) with Alzheimer's amyloide-peptide (A beta) across the vascular membranes of the central nervous system (CNS). Here we show the presence of gp330/megalin mRNA and gp330-like immunoepitopes in brain capillaries and choroid plexus and their absence from brain parenchyma. By polymerase chain reaction (PCR) we estimated 1.2 x 10(5) molecules (1 pg) of gp330/megalin mRNA/mu g total brain capillary RNA, which is 3% of that in kidney RNA. However, gp330 mRNA was not detected by in situ hybridization in vascular CNS tissue, presumably because of low transcript prevalence. The ratio of gp330 protein:RNA was 17-fold higher in choroid plexus vs brain capillaries, which implies tissue specific regulation of the protein and mRNA prevalence. We conclude that gp330/megalin mRNA and protein are expressed in brain capillaries and choroid plexus in small amounts that are consistent with the observed activities of this endocytosing receptor in the regulation of apoJ and A beta uptake by the CNS. (C) 1999 Academic Press.
引用
收藏
页码:194 / 201
页数:8
相关论文
共 43 条
[1]  
ABBATE M, 1993, EUR J CELL BIOL, V61, P139
[2]   LDL-receptor structure - Calcium cages, acid baths and recycling receptors [J].
Brown, MS ;
Herz, J ;
Goldstein, JL .
NATURE, 1997, 388 (6643) :629-630
[3]   Expression of the very low-density lipoprotein receptor (VLDL-r), an apolipoprotein-E receptor, in the central nervous system and in Alzheimer's disease [J].
Christie, RH ;
Chung, H ;
Rebeck, GW ;
Strickland, D ;
Hyman, BT .
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, 1996, 55 (04) :491-498
[4]   A new function for the LDL receptor: Transcytosis of LDL across the blood-brain barrier [J].
Dehouck, B ;
Fenart, L ;
Dehouck, MP ;
Pierce, A ;
Torpier, G ;
Cecchelli, R .
JOURNAL OF CELL BIOLOGY, 1997, 138 (04) :877-889
[5]  
FARQUHAR MG, 1995, J AM SOC NEPHROL, V6, P35
[6]   THE UNFOLDING STORY OF MEGALIN (GP330) - NOW RECOGNIZED AS A DRUG RECEPTOR [J].
FARQUHAR, MG .
JOURNAL OF CLINICAL INVESTIGATION, 1995, 96 (03) :1184-1184
[7]   SIGNIFICANCE OF RARE MESSENGER-RNA SEQUENCES IN LIVER [J].
GALAU, GA ;
KLEIN, WH ;
BRITTEN, RJ ;
DAVIDSON, EH .
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 1977, 179 (02) :584-599
[8]   Interaction of apolipoprotein J-amyloid beta-peptide complex with low density lipoprotein receptor-related protein-2 megalin - A mechanism to prevent pathological accumulation of amyloid beta-peptide [J].
Hammad, SM ;
Ranganathan, S ;
Loukinova, E ;
Twal, WO ;
Argraves, WS .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1997, 272 (30) :18644-18649
[9]   CLUSTERIN - THE INTRIGUING GUISES OF A WIDELY EXPRESSED GLYCOPROTEIN [J].
JENNE, DE ;
TSCHOPP, J .
TRENDS IN BIOCHEMICAL SCIENCES, 1992, 17 (04) :154-159
[10]  
JOIKEN EV, 1994, J BIOL CHEM, V269, P26411